Oragenics appoints James Kelly as chief medical officer

Oragenics announced it has appointed James Kelly as its chief medical officer, to oversee its upcoming Phase II clinical trial. Oragenics’ drug candidate, ONP-002 is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury, or TBI, aka concussion. ONP-002 is a new chemical entity designed to target the brain through delivery into the nasal cavity and onward to the brain. A 40-patient Phase I study was completed and showed the drug to be safe and well-tolerated.